$2.03
▼ -0.5% Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX)
How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing
Overview
52-week range
$1.61
$6.88
8% of range
Avg surprise (last 3)
-2.6%
Avg reaction (last 2)
+0.8%
100% positive
Latest IV / EM
91%
EM ±20.8% · $2 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-0.10 | $-0.10 | 0.0% | +16.7% | +0.5% | earnings |
| Mon Aug 11, 2025 | Jun/2025 | $-0.14 | $-0.13 | -7.7% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.12 | $-0.12 | 0.0% | — | +1.1% | earnings |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$0.10 | -$0.14 | +28.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | — | — | $0 | $850,000 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-20M | — | $-16M | $-21M | $-18M | — | $-12M | $-15M |
| Net income | $-18M | — | $-14M | $-20M | $-17M | — | $-10M | $-13M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $55M | $31M | $46M | $23M | $41M | $43M | $19M | $19M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $196M | $210M | $221M | $106M | $124M | $133M | $141M | $154M |
| Total assets | $205M | $220M | $231M | $117M | $131M | $140M | $149M | $156M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $19M | $23M | $22M | $23M | $21M | $15M | $11M | $10M |
| Total equity | $186M | $197M | $210M | $93M | $110M | $125M | $138M | $146M |